Ar­gos’ PhI­II for its per­son­al­ized can­cer vac­cine im­plodes dur­ing an in­ter­im analy­sis

Ar­gos Ther­a­peu­tics’ $ARGS Phase III study of its per­son­al­ized can­cer vac­cine ro­ca­pulden­cel-T has end­ed in dis­as­ter. Its in­de­pen­dent mon­i­tor­ing com­mit­tee con­clud­ed in an in­ter­im analy­sis that the late-stage tri­al for metasta­t­ic re­nal cell car­ci­no­ma was head­ed to a near cer­tain fail­ure, call­ing for an end to the study.

Ar­gos treat­ment is de­signed to cap­ture the anti­gens spe­cif­ic to a pa­tients’ tu­mor cells, ramp­ing up an im­mune re­sponse to wipe out those can­cer cells. In­ves­ti­ga­tors com­bined their drug with Su­tent (suni­tinib) and com­pared it to stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER